IQVIA's (NYSE:IQV) Q3 2026: beats on revenue

What happened

IQVIA reported Q3 2026 revenue of $4.43 billion, up 8% from a year earlier and above analysts' consensus estimate of $4.36 billion. Adjusted profit was $3.34 per share, 2% above estimates, and the company slightly raised full-year revenue guidance to $17.43 billion.

Confirmed

Global impact / market context

Beating revenue and profit expectations suggests IQVIA is winning more business from drugmakers that pay for clinical research and data services. The small guidance increase signals management expects that demand to continue, which supports future revenue and helps explain the stock's valuation.

Analyst inference

Revenue guidance of $17.43 billion is close to analysts' consensus, so the beat was modest rather than a major surprise. Free cash flow margin fell to 15.1% from 18.8%, which means less cash available from each dollar of sales, a point investors may weigh against the profit beat.

Analyst inference

What to watch

1. Free cash flow margin fell to 15.1% from 18.8% a year earlier, so watch whether this decline continues and whether it limits cash available for buying back stock or paying down borrowed money. Confirmed
2. Watch whether IQVIA delivers the raised full-year revenue guidance of $17.43 billion and adjusted profit of $12.95 per share, since missing either target could reverse the boost from this quarter's beat. Proposed
3. Constant currency revenue growth, which strips out currency swings, rose 8.6% versus 3.9% a year earlier, so watch whether this faster underlying growth persists once currency effects are excluded from reported results. Analyst inference

Evidence

• stockstory.org